Treatment of U2OS cells with UNC0638 disrupted BRCA-BARD retention at DNA damage sites (Wu et al., 2015). The use of the PARP inhibitor Olaparib in combination with UNC0638 also resulted in a synergistic reduction of clonogenic survival in breast cancer cells (Carvalho et al., 2014). This evidence concerns the gene PARP1 and breast carcinoma.